Page 2 - Prnewswire Chemomab Therapeutics Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prnewswire chemomab therapeutics ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prnewswire Chemomab Therapeutics Ltd Today - Breaking & Trending Today

Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare. ....

Wadi Mor , Barbara Lindheim , Strategic Communications , Chemomab Therapeutics Ltd , Prnewswire Chemomab Therapeutics Ltd , Chief Executive Officer , Chief Scientific Officer , Annual Global Investment Conference , Vice President , Chemomab Therapeutics ,

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

Includes Extensive Data Showing that CM-101, Chemomab s CCL24-Neutralizing Antibody, Interrupts the Fibro-Inflammatory Processes that Lead to PSC
TEL AVIV, Israel, June 28, 2023 /PRNewswire/ Chemomab Therapeutics Ltd. (Nasdaq: CMMB), . ....

City Of , United Kingdom , Irina Koffler , Barbara Lindheim , Douglas Thorburn , Wadi Mor , Prnewswire Chemomab Therapeutics Ltd , Digestive Health Division , Chemomab Therapeutics Ltd , Lifesci Advisors , Digestive Health , Strategic Communications , Institute Of Liver , Includes Extensive Data Showing , Neutralizing Antibody , Fibro Inflammatory Processes , Divisional Medical Director , Royal Free London , Principal Investigator , Private Securities Litigation Reform , Vice President , Sci Advisors ,

Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023

/PRNewswire/ Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare. ....

Barbara Lindheim , Wadi Mor , Raanan Greenman , Rifaat Safadi , Avi Katav , John Lawler , Homer Levi , Douglas Thorburn , Chris Cirillo , Irina Koffler , Matthew Frankel , Shelia Sherlock , Tom Snir , Christopher Bowlus , Ilan Vaknin , Massimo Pinzani , Hepatology At University College London , Prnewswire Chemomab Therapeutics Ltd , Digestive Health , Institute For Liver , Data Monitoring Committee , Strategic Communications , Lifesci Advisors , Chemomab Therapeutics Ltd , New Proteomics Data Further Confirms , Sclerosing Cholangitis ,

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

─Adi Mor, PhD, Co-founder, Board Director and Chief Scientific Officer, Reappointed to CEO Role─
─Sigal Fattal, Vice President Finance, Reappointed as. | June 5, 2023 ....

Wadi Mor , Sigal Fattal , Nissim Darvish , Barbara Lindheim , Donald Marvin , Dale Pfost , Irina Koffler , Tel Aviv University , Strategic Communications , Prnewswire Chemomab Therapeutics Ltd , Us National Institutes Of Health , Chemomab Therapeutics Ltd , Lifesci Advisors , Board Director , Chief Scientific Officer , Vice President Finance , Data Readout , Latter Part , Implementing Further Reorganization , Efficiency Measures Intended , Extend Cash Runway , After Expected , Appointed Chairman , Chief Executive Officer , Chief Financial Officer , Vice President ,

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

/PRNewswire/ Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of. ....

United Kingdom , Rebecca Ross , Hilit Levi , Ilan Vaknin , Irina Koffler , Wadi Mor , Barbara Lindheim , Prnewswire Chemomab Therapeutics Ltd , Strategic Communications , European Congress , Lifesci Advisors , Leeds Institute Of Rheumatic , Chemomab Therapeutics Ltd , University Of Leeds , European Alliance Of Association , New Patient Data Further Implicates , Fibrotic Disease Pathology , Neutralizing Antibody , Systemic Sclerosis , European Alliance , Italy May , Professor Enrico De Lorenzis , Leeds Institute , Musculoskeletal Diseases , Professor De Lorenzis , Chief Scientific Officer ,